Key Highlights
- Net loss per share was USD 0.42 against an estimate of a USD 0.44 loss.
- Net loss was USD 17.90 million, compared with USD 18.23 million.
- Research and development expenses were USD 14.55 million, compared with USD 13.65 million.
- Cash, equivalents and investments were USD 77.8 million at September 30, 2026.
Acrivon Therapeutics (NASDAQ:ACRV) reported a net loss of USD 17.90 million for the third quarter of 2026, compared with USD 18.23 million in the prior-year quarter. Basic and diluted net loss per share was USD 0.42, compared with USD 0.47, against an estimate of a USD 0.44 loss.
The company reported no Revenue in either period. It describes itself as a clinical-stage biotechnology company developing precision medicines using its proprietary Acrivon Predictive Precision Proteomics, or AP3, platform.
Third Quarter Results
Research and development expenses were USD 14.55 million, compared with USD 13.65 million, and general and administrative expenses were USD 3.97 million, compared with USD 6.04 million. Total operating expenses were USD 18.52 million, compared with USD 19.69 million, and the loss from operations was USD 18.52 million, compared with USD 19.69 million.
Interest income was USD 748 thousand, compared with USD 1.51 million, and other expense, net, was USD 127 thousand, compared with USD 53 thousand. Total other income, net, was USD 621 thousand, compared with USD 1.45 million. Weighted average common stock outstanding was 42,876,572, compared with 38,560,464.
Nine-Month Results
For the nine months ended September 30, 2026, Research and Development expenses were USD 43.56 million, compared with USD 45.24 million, and general and administrative expenses were USD 13.53 million, compared with USD 18.75 million. The loss from operations was USD 57.09 million, compared with USD 64.00 million.
The net loss for the nine months was USD 54.90 million, compared with USD 58.92 million, and net loss per share was USD 1.33, compared with USD 1.53. The comprehensive loss was USD 55.04 million, compared with USD 59.26 million.
Balance Sheet and Cash Runway
Cash and cash equivalents were USD 47.54 million at September 30, 2026, compared with USD 41.50 million at December 31, 2025, and short-term investments were USD 30.22 million, compared with USD 77.08 million. Cash, cash equivalents and investments totaled USD 77.8 million, which the company believes is sufficient to fund its operating expenses and Capital Expenditure requirements into the fourth quarter of 2027. The filing's Liquidity discussion also notes the company's evaluation of its ability to continue as a Going Concern under applicable accounting guidance.
Total Assets were USD 85.75 million, compared with USD 129.72 million, and total current liabilities were USD 14.28 million, compared with USD 15.66 million. Total liabilities were USD 14.97 million, compared with USD 17.20 million. The filing discusses the company's need for additional capital to finance its operations and the potential need to delay, reduce or terminate its research and development programs.
Acrivon Therapeutics Q3 2026 Earnings: Key Takeaways
Acrivon Therapeutics reported a third quarter 2026 net loss of USD 17.90 million and research and development expenses of USD 14.55 million. Cash, cash equivalents and investments totaled USD 77.8 million at September 30, 2026.






Please wait processing your request...